The evolving pharmacotherapy of pulmonary fibrosis

Bibliography

• Winterbauer RH, Hammar SP, Hallman KO, Diffuse interstitial pneumonitis: clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. Am J Med 1978;65:661-72
   PubMed Web of Science ®Google Scholar
• Raghu G, Depaso WJ, Cain K, Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991;144:291-6
   PubMed Web of Science ®Google Scholar
• American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304. Review. No abstract available. Erratum in: Am J Respir Crit Care Med2002 Aug 1;166:426
   Google Scholar
• Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-51
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824
   PubMed Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis Clinical Research Network. Raghu G, Anstrom KJ, King TE Jr, Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-77
   PubMed Web of Science ®Google Scholar
• Ziesche R, Hofbauer E, Wittmann K, A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264-9
   PubMed Web of Science ®Google Scholar
• Raghu G, Brown KK, Bradford WZ, Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-33
   PubMed Web of Science ®Google Scholar
• King TE Jr, Albera C, Bradford WZ, INSPIRE Study Group. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009;374:222-8
   PubMed Web of Science ®Google Scholar
• Zisman DA, Schwarz M, Anstrom KJ, Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010;363:620-8
   PubMed Web of Science ®Google Scholar
• Clozel M, Salloukh H. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med 2005;37:2-12
   PubMed Web of Science ®Google Scholar
• King TE Jr, Behr J, Brown KK, BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:75-81
   PubMed Web of Science ®Google Scholar
• King TE Jr, Brown KK, Raghu G, BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:92-9
   PubMed Web of Science ®Google Scholar
• Cantin AM, North SL, Fells GA, Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest 79:1987;1665-73
   PubMed Web of Science ®Google Scholar
• Strausz J, Muller-Quernheim J, Steppling H, Ferlinz R. Oxygen radical production by alveolar inflammatory cells in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1990;141:124-8
   PubMed Web of Science ®Google Scholar
• Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989;139:370-2
   PubMed Web of Science ®Google Scholar
• Behr J, Maier K, Degenkolb B, Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis: adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997;156:1897-901
   PubMed Web of Science ®Google Scholar
• Demedts M, Behr J, Buhl R, IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42
   PubMed Web of Science ®Google Scholar
• Hecker L, Vittal R, Jones T, NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009;15:1077-81
   PubMed Web of Science ®Google Scholar
• Amara N, Goven D, Prost F, NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. Thorax 2010;65:733-8
   PubMed Web of Science ®Google Scholar
• Borbely G, Szabadkai I, Horvath Z, Small-molecule inhibitors of NADPH oxidase 4. J Med Chem 2010;53:6758-62
   PubMed Web of Science ®Google Scholar
• Laleu B, Gaggini F, Orchard M, First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem 2010;53:7715-30
   PubMed Web of Science ®Google Scholar
• Maher TM. Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today (Barc) 2010;46:473-82
   PubMed Web of Science ®Google Scholar
• Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999;291:367-73
   PubMed Web of Science ®Google Scholar
• Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 1999;276:L311-18
   PubMed Web of Science ®Google Scholar
• Oku H, Shimizu T, Kawabata T, Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008;590:400-8
   PubMed Web of Science ®Google Scholar
• Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent,pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999;159:1061-9
   PubMed Web of Science ®Google Scholar
• Azuma A, Nukiwa T, Tsuboi E, Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-7
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Ebina M, Kondoh Y, Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:821-9
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9
   PubMed Web of Science ®Google Scholar
• Beyer C, Distler JH. Tyrosine kinase signaling in fibrotic disorders: translation of basic research to human disease. Biochim Biophys Acta 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Daniels CE, Wilkes MC, Edens M, Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114(9):1308-16
   PubMed Web of Science ®Google Scholar
• Akhmetshina A, Dees C, Pileckyte M, Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008;22:2214-22
   PubMed Web of Science ®Google Scholar
• Daniels CE, Lasky JA, Limper AH, Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010;181(6):604-10
   PubMed Web of Science ®Google Scholar
• Richeldi L, Costabel U, Selman M, Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-87
   PubMed Web of Science ®Google Scholar
• Scotton CJ, Krupiczojc MA, Konigshoff M, Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 2009;119:2550-63
   PubMed Web of Science ®Google Scholar
• Maher TM. Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment. Clin Chest Med 2012;33:69-83
   PubMed Web of Science ®Google Scholar
• Kubo H, Nakayama K, Yanai M, Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005;128:1475-82
   PubMed Web of Science ®Google Scholar
• Noth I, Anstrom KJ, Calvert SB, for the Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;186:88-95
   PubMed Web of Science ®Google Scholar
• Zhu Z, Homer RJ, Wang Z, Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999;103:779-88
   PubMed Web of Science ®Google Scholar
• Jakubzick C, Choi ES, Joshi BH, Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. J Immunol 2003;171:2684-93
   PubMed Web of Science ®Google Scholar
• Kolodsick JE, Toews GB, Jakubzick C, Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol 2004;172:4068-76
   PubMed Web of Science ®Google Scholar
• Gu L, Tseng S, Horner RM, Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000;404(6776):407-11
   PubMed Web of Science ®Google Scholar
• Murray LA, Argentieri RL, Farrell FX, Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2. Int J Biochem Cell Biol 2008;40:2174-82
   PubMed Web of Science ®Google Scholar
• Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994;7:515-18
   PubMed Web of Science ®Google Scholar
• Raghu G, Brown KK, Costabel U, Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008;178:948-55
   PubMed Web of Science ®Google Scholar
• Goh NS, Desai SR, Veeraraghavan S, Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177:1248-54
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66
   PubMed Web of Science ®Google Scholar
• Goldin J, Elashoff R, Kim HJ, Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 2009;136(5):1333-40
   PubMed Web of Science ®Google Scholar
• Hoyles RK, Ellis RW, Wellsbury J, A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70
   PubMed Web of Science ®Google Scholar
• Renzoni EA. Interstitial lung disease in systemic sclerosis. Monaldi Arch Chest Dis 2007;67:217-28
   Google Scholar
• Boin FT. Cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum 2008;58:1165-74
   PubMed Web of Science ®Google Scholar
• Atamas SP, Yurovsky VV, Wise R, Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999;42:1168-78
   PubMed Web of Science ®Google Scholar
• Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004;4:583-94
   PubMed Web of Science ®Google Scholar
• Seibold JR, Denton CP, Furst DE, Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 2010;62:2101-8
   PubMed Web of Science ®Google Scholar
• Khanna D, Saggar R, Mayes MD, A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 2011;63:3540-6
   PubMed Web of Science ®Google Scholar
• Perosa F, Prete M, Racanelli V, Dammacco F. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med 2010;267:260-77
   PubMed Web of Science ®Google Scholar
• Keir GJ, Maher TM, Hansell DM, Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 2012; Epub ahead of print
   Google Scholar
• Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 2009;48:968-71
   PubMed Web of Science ®Google Scholar
• Daoussis D, Liossis SN, Tsamandas AC, Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010;49:271-80
   PubMed Web of Science ®Google Scholar
• Khanna D, Brown KK, Clements PJ, Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. Clin Exp Rheumatol 2010;28:S55-62
   Google Scholar
• Kim EJ, Collard HR, King TE. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 2009;136:1397-405
   PubMed Web of Science ®Google Scholar
• Kim EJ, Elicker BM, Maldonado F, Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010;35:1322-8
   PubMed Web of Science ®Google Scholar
• de Lauretis A, Veeraraghavan S, Renzoni E. Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis 2011;8:53-82
   PubMed Web of Science ®Google Scholar
• Moller DR, Forman JD, Liu MC, Enhanced expression of IL-12 associated with Th 1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996;156:4952-60
   PubMed Web of Science ®Google Scholar
• Ziegenhagen MW, Rothe E, Zissel G, Exagerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:185-90
   PubMed Web of Science ®Google Scholar
• Hapke EJ, Meek JC. Steroid treatment in pulmonary sarcoidosis. In: Levinsky L, Macholda F, editors. Proc 5th International Conference on Sarcoidosis. 1st edition. Universita Karlova, Prague; 1971. p. 621-5
   Google Scholar
• Young RL, Harkelroad LE, Lorden RE, Pulmonary sarcoidosis: a prospective evaluation of glucocorticoid therapy. Ann Intern Med 1970;73:207-12
   Web of Science ®Google Scholar
• Israel HF, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis 1973;107:609-14
   PubMed Web of Science ®Google Scholar
• Mikami R, Hitagi Y, Iwai K, A double blind controlled trial on the effect of corticosteroid therapy in sarcoidosis. In: Iwai K, Hosoda Y, editors. Proc International Conference on Sarcoidosis. 1st edition. University of Tokyo Press, Tokyo; 1974. p. 533-8
   Google Scholar
• Selroos O, Sellergen T-L. Corticosteroidtherapy of pulmonary sarcoidosis: a prospective evaluation of alternate day and daily dosage in stage II disease. Scand J Respir Dis 1979;60:215-21
   PubMedGoogle Scholar
• Eule H, Roth I, Weide W. Clinical and functional results of a controlled clinical trial of the value of prednisolone therapy in sarcoidosis. In: Jones-Williams W, Davies BH, editors. Proc. International Conference on Sarcoidosis. 1st edition. Alpha Omega, Cardiff; 1980. p. 624-31
   Google Scholar
• Yamamoto M, Saito N, Tachibana T, Effects of an 18-month corticosteroid therapy on stage I and stage II sarcoidosis patients (a control trial). In: Proc. 9th International Conference on Sarcoidosis. 1st edition. Pergamon Press, Oxford; 1983. p. 470-4
   Google Scholar
• Hunninghake GW, Gilbert S, Pueringer R, Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994;149:893-8
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Kavuru M, For the Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795-802
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Barnathan ES, Lo K, C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2010;27:49-56
   PubMed Web of Science ®Google Scholar
• Prasse A, Zissel G, Lutzen N, Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med 2010;182:540-8
   PubMed Web of Science ®Google Scholar
• Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 2007 Nov;30:835-9
   PubMed Web of Science ®Google Scholar